Posted on 2/8/21
2021’s Healthiest & Unhealthiest Cities in America – WalletHub Study
With health care costs rising and the U.S. facing one of the worst health crises in decades with the COVID-19 pandemic, the personal-finance website WalletHub today . . .
Posted on 2/8/21
SmartBreast Acquires Molecular Breast Imaging Assets from GE Healthcare
SmartBreast Corporation, a privately held company focused on breast cancer screening and diagnosis, announced today that it has acquired the Discovery NM750b Molecular Breast Imaging (MBI) . . .
Posted on 2/8/21
Gemini Therapeutics Debuts as Publicly Traded Precision Medicine Company Focused on Age-Related Macular Degeneration
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced the completion of its . . .
Posted on 2/8/21
Moderna Short Interest Is Rising. Here's Why I'm Not Worried
Short interest in a stock is rarely good news. It signals a lack of faith in a stock's future. And as we saw recently with GameStop . . .
Posted on 2/6/21
Ambu Expands Single-Use Endoscopy Contracts with Two U.S. Group Purchasing Organizations
With the expansion of two existing GPO contracts, Ambu’s position in single-use endoscopy continues to strengthen Ambu Inc., the world leader in single-use endoscopes, announced today . . .
Posted on 2/5/21
Vor Biopharma Prices of IPO
CAMBRIDGE, Mass., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted . . .
Posted on 2/5/21
Here's How Novavax's Vaccine Stacks Up Against Moderna's and Pfizer's
Novavax (NASDAQ:NVAX) shares climbed 2,700% last year as investors bet on the biotech company's investigational coronavirus vaccine. But the share price's story doesn't end there. Last . . .
Posted on 2/5/21
How Bristol Myers Squibb's Celgene Buyout Continued to Pay Off in Q4
No one likes to miss the big party. But shareholders of Bristol Myers Squibb (NYSE:BMY) probably feel like they did in 2020. Shares of the drugmaker . . .
Posted on 2/5/21
Rhythm Pharmaceuticals Prices of Public Offering
BOSTON, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare . . .
Posted on 2/4/21
Northern Westchester Hospital Opens State-of-the-art Electrophysiology Lab
Dr. Subbarao Choudry leads program Northern Westchester Hospital’s (NWH) has opened a state-of-the-art Electrophysiology Lab, offering specialized testing, expert diagnosis and advanced treatment for all types . . .
Posted on 2/4/21
EyePoint Pharmaceuticals Closes of $115 Million Public Offering of Common Stock
WATERTOWN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing therapeutics to help improve the . . .
Posted on 2/4/21
Alexion Reports Fourth Quarter and Full Year 2020 Results
BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the fourth quarter and full year of 2020. Total revenues for the full year of 2020 . . .
Posted on 2/4/21
Biogen Cash Tender Offer for 5.200% Senior Notes
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the commencement of an offer to purchase for cash any and all . . .
Posted on 2/4/21
Biogen Announces Private Exchange Offer for 5.200% Senior Notes
CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the commencement of a private offer to exchange any and all of . . .
Posted on 2/4/21
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
WOBURN, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, today . . .
Posted on 2/4/21
Why Biogen's Q4 Results Were a Bust
You can almost always know how strong a company's near-term prospects are by looking at its stock price. Biogen's (NASDAQ:BIIB) shares sank more than 17% last . . .
Posted on 2/4/21
Rhythm Pharmaceuticals Proposed Public Offering
BOSTON, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare . . .
Posted on 2/4/21
Translate Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative . . .
Posted on 2/4/21
Kaleido Biosciences Proposes Public Offering of Common Stock
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome . . .
Posted on 2/4/21
Sensei Biotherapeutics Prices of Upsized IPO
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation . . .
Posted on 2/4/21
Sensei Biotherapeutics Announces Pricing of Upsized IPO
BOSTON and ROCKVILLE, Md., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation . . .
Posted on 2/4/21
Kaleido Biosciences Prices Public Offering of Common Stock
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbiome . . .
Posted on 2/3/21
Reverie Labs Raises $25M Series A Round
Reverie Labs, a pharmaceutical company pioneering the application of machine learning to developing next-generation small molecule kinase inhibitors, today announced the closure of its $25M Series . . .
Posted on 2/3/21
Boston Scientific Announces Results For Fourth Quarter And Full Year 2020
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.708 billion during the fourth quarter of 2020. This represents a decline of (6.8) percent on a . . .
Posted on 2/3/21
Yield10 Bioscience Closes of $12.7 Million Public Offering
WOBURN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN), an agricultural bioscience company, today announced the closing of its previously announced underwritten . . .
Boston
